This is with great pride the Seminars in Cardiothoracic and Vascular Anesthesia introduces its first themed issue of 2019 on the contemporary management of mitral valve (MV) disease and its related conditions. This themed issue has been created in response to meet the demand on trying to understand what constitutes the contemporary assessment and management of MV disease ( Figure 1 ). MV disease is relatively prevalent both in the developed and developing countries, although the etiologies vary widely. The majority of North America, Europe, and Australia predominantly see degenerative MV disease as the most frequently occurring etiology for MV disease, whereas in Asia, Latin America, and Africa the etiology of MV disease is still predominantly rheumatic heart disease. Therefore, as expected from the etiologies the former geographic locations are more likely to see middle to older age group patients as compared with the younger age group in the latter geographic areas. Given abundance in cyber-knowledge and unlimited access to information on different management options for MV disease, it is not infrequent to have a patient with certain expectations when it comes to discussing and deciding on the best available treatment modalities for MV disease.
The present themed issue comprehensively covers multiple aspects of MV disease assessment and management. The editors have astutely tried to identify and focus on areas to bridge the knowledge gap that exits in this specific area. Common MV pathologies involve mitral stenosis, mitral regurgitation (MR), atrial fibrillation in MV disease, and MV disease with coronary artery disease. Contemporary aspects are the evolution of guidelines in the face of emerging evidence: newer less invasive percutaneous and hybrid approaches to treating MV disease, therapy for mitral annular calcification (MAC) 2, 3 left atrial appendage occlusion in arrhythmia in patients with high risk for bleeding, 4 and MV disease in setting of mechanical circulatory support devices like left ventricular assist devices (LVAD). Summarized recently in a series by Nishimura and colleagues, 5 the most recent controversies in treatment of MV disease involves the following: (1) timing of surgery; (2) correction of secondary MV regurgitation and impact on survival and quality of life; (3) need for reference centers for MV repairs; (4) advantages of minimally invasive approach over sternotomy; (5) MitraClip for intermediate and high-risk primary MR; (6) role of MitraClip in secondary MR; (7) effectiveness of novel transcatheter mitral annuloplasty; (8) effectiveness of transcatheter MV replacement (TMVR); and (9) effectiveness of balloon expandable valve replacement in nonrheumatic mitral stenosis due to MAC. [5] [6] [7] Also, there is a novel concept of whether endocarditis always requires valve replacement or should the primary treatment be repair whenever possible? 8 Is minimally invasive approach better than conventional sternotomy given preserved right ventricular (RV) function as with lateral pericardiotomy versus midline pericardiotomy? 9 Innovative ideas into the type of valve selection in light with ongoing perfection of valve-in-valve techniques 10 ; should we be replacing valves using bioprosthetic preferably over mechanical valves? The answer probably lies in complementary procedures rather than collateral procedures. Considering all these aspects and variables, Adams and his group are big proponents in favor of the idea for creating hierarchical "reference centers" for MV disease treatment. 11, 12 The concept is reasonable, but the implementation and execution could potentially pose an infrastructural challenge and of course the outcome and results of repair versus replacement may vary between low-volume and high-volume centers. 13 In that respect, the recommendations of the American College of Cardiology/American Heart Association Guidelines for Valvular Heart Disease has placed MV surgery for asymptomatic patient with no functional and structural compromise as Class IIb indication for surgery.
14 Every noble intention to repair an asymptomatic MR stipulates a contemplation into potential MV replacement as a complication. 13 Conceptual revolution in approach to MV disease treatment had been introduced by Carpentier. 15 His inception of prioritizing MV repair over replacement has stayed and evolved over the years. Perception of surgical techniques beyond the leaflet resection like neochordoplasty has emerged. Of recent, Dreyfus and colleagues suggested a combined approach partial resection along with neochords. 16 Key to all innovations when it comes to the management of MV disease has been the change in the concept on how MV is viewed, that is, the entire MV apparatus rather than just focusing on the actual MV leaflets. Percutaneous approaches to treating the specific aspects of MV apparatus has transpired. Emerging diagnostic workup with advent of 3-dimensional (3D) echocardiography (Figures 2 and 3 ), MV calcium scoring on magnetic resonance imaging, and even 3D printing have only led to improved understanding of the disease process and therapeutic avenues. 17 Deeper understanding of the disease process affecting the MV apparatus, spectrum of therapeutic options, and emerging outcomes from various clinical trials compel us to think beyond just overall mortality and morbidity, but enable us to offer "customized" treatment options addressing the best needs and goals for an individual patient. For example, going for a total surgical correction or repair of MV regurgitation in an otherwise 40-year-old patient who still wants to run marathons versus a percutaneous minimally invasive approach to MV repair for a 75-year-old grandmother with multiple comorbidities whose objective in life is to be able to perform her day-to-day activities and live to see her grandchild's first birthday.
The articles compiled for this issue have striven to keep the read succinct by selecting contemporary aspects in the field of MV disease and its management, keeping the reader engaged through each topic. Nonaka and Fox, 18 have done a great job highlighting the evolution of the guideline-wordings in face of evolving evidence for ischemic MV repair. They dissected the trials nicely leading to a conclusion, as of now, that symptomatic ischemic MR (secondary MR) despite medical optimization may be best served by valve replacement than repair. In the context of secondary MR, results of 2 much anticipated trials were recently published, the Cardiovascular Assessment of the MitraClip Percutaneous Therapy in heart failure patients with functional MR (COAPT) trail 19 and the Mitra Clip Device for severe Functional/Secondary Mitral Regurgitation (MITRA-FR) trial. 20 The COAPT trail on one hand opens doors to a new percutaneous therapy pathway, whereas the MITRA-FR trail on the other hand has stirred up some controversy regarding the efficacy of percutaneous repair with its contrasting results. Inherently, COAPT has published 2-year follow-up results as compared with 1-year results for MITRA-FR. COAPT shows markedly improved primary end points (mortality and heart-failure readmissions) in patients receiving MitraClip for secondary MR whereas noninferiority in MITRA-FR between patients with medical management and MitraClip procedure. There has been a difference in selection criteria for patients with effective regurgitation orifice area of 0.2 (MITRA-FR) versus 0.4 (COAPT), left ventricular end systolic diameter smaller (MITRA-FR) versus bigger (COAPT), and arguably better optimization of heart failure decided by a committee in COAPT versus MITRA-FR. Despite the fact that COAPT has been an industry-funded trial, the results need to be critically analyzed. The entire impact of these results on the cardiology-cardiac surgery community is yet awaited, but still one wonders that if surgical repair failed to yield outcome benefit 21 how come percutaneous "incomplete" correction has the potential to yield better results? After all, is it just the atrial septal defect left behind after MitraClip that is resulting in these morbidity and mortality benefit in these patients with endstage severely symptomatic heart failure?
Out of all aspects of MV treatment the most intriguing continues to be MV regurgitation. Performed at the right time in the right hands, success of MV repair is excellent. 22 So much so, that ideally optimal time of surgery has been suggested to be anytime between onset of severe MR to any time before LV dilatation left ventricular end systolic diameter >4 cm or LV dysfunction. 22 In order to proceed down the treatment pathway for any MR determining the etiology or mechanism is the core starting point. For primary MR, the functional classification of Carpentier still holds good. 15 Secondary MR may be divided into 3 etiologic types: (1) ischemic MR; (2) nonischemic cardiomyopathy related MR; and (3) atrial MR related to atrial enlargement from arrhythmia. 22 Since the guidelines suggest surgical intervention even before onset of symptoms in primary MR, it is crucial to identify absolute etiopathology in order to yield the best results for MV repair. If primary MR is due to prolapse of posterior leaflet only with no MAC and no more than mild annular dilatation, "early operation" may be a better idea, whereas for the ones due to prolapse of anterior or bileaflet prolapse, mild to moderate calcification, moderate to severe annular dilatation, or etiologies like perforation, cleft, or rheumatic heart disease, "watchful waiting" may be a reasonable option. 22, 23 In an attempt to intercept the intricateness of MV repair various groups have come up with their own complexity-scoring systems. One such complexity-predicting scoring system developed and used by the University of West Virginia is described in the article by Badhwar and colleagues. 24 Another similar complexityscoring system noteworthy of mentioning here, developed by Adams and his group, 1 is based on direct surgical observation of the valve and preoperative transesophageal echocardiography (TEE) classifying the repair into "simple," "intermediate," and "complex." 16 Bhatia and colleagues provide an excellent review on the 3D TEE for MV anatomy. 25 Understanding the applied anatomy is not only important for direct surgical evaluation for repair and percutaneous repair of the valve but also for guiding the interventionist or surgeon in procedures like percutaneous or surgical closure of paravalvular leaks (PVL). 26, 27 Paravalvular leak after MV replacement is mostly treated through minimally invasive approach expect for patients with endocarditis, or patients with significant hemodynamic compromise secondary to PVL. 28 Understanding the "clock-face" anatomy of MV and aortic valve is vital as correlations with TEE and catheterization are made for successful closure of PVL. Mitrev and colleagues discuss other more traditional catheter-based interventions like balloon valvotomies for MV stenosis in alignment with the guidelines of the American College of Cardiology/American Heart Association for the management of patients with valvular heart disease. 29, 30 They contribute a succinct summary on percutaneous, catheter-based methods for closure of PVLs. Continuing on the same topic, Nyman and colleagues 31 review in detail the implications of TMVR either valve-in-valve and valve-in-ring procedures, which are becoming more common and frequent. Noteworthy is that they bring forward the novel concept of neo-LVOT as first published by Blanke and colleagues. 32 Lombard and Liang review atrial fibrillation (AF) in context with MV disease. 33 Emphasis is on the fact that new-onset AF in patient with asymptomatic MR may raise the need for a surgical correction for MR. 33 Most of morbidity in AF patients revolves around the concept of thrombus formation and embolization. Both epicardial and endocardial ablation techniques have been utilized (CoxMaze). These maybe executed percutaneously or as openheart surgical procedures. Left atrial appendage exclusion has been a standard technique whenever patient is undergoing conventional median sternotomy. Once novel techniques of left atrial appendage exclusion by epicardial techniques like AtriClip by video-assisted thoracoscopy or sternotomy approach or intracardiac technique like Amplatzer Amulet and Watchman Device have been widely adopted. 4 Any contraindication to anticoagulation with persistent atrial fibrillation is the most important indication for intracardiac exclusion device. 4 The review by Deegan and colleagues 34 discusses the different available devices. Strength of the review is the nicely described imaging techniques and step-by-step guidance.
MV disease is known to affect the cardiopulmonary physiology and also the other associated anatomic structures. Hence the emphasis on early intervention for MV repair or replacement whenever appropriate. Del Rio and colleagues impart a detailed review on RV pathophysiology in left heart disease in context of MV disease. 35 Different aspects of pulmonary hypertension are reviewed, and highlight the concept of diastolic pressure gradient, which is a more sensitive and specific maker for identifying contribution of precapillary component in case of "mixed" pulmonary artery hypertension. Nicoara and colleagues present their review on functional tricuspid valve (TV) regurgitation in MV disease, which a great complementary addition to the review by Del Rio and colleagues on RV dysfunction in MV disease. 36 Their review does an excellent work with reviewing the current controversy around the feasibility of doing TV repair in patients undergoing MV surgery and having a TV annulus >4 cm. This accuracy of this conventional approach has recently been challenged by David and colleagues. 37 Henceforth, unless the tricuspid regurgitation is severe or, moderate to severe along with diameter >4 cm in the TEE 4-chamber view, clinicians may arguably refrain from any additional TV intervention.
Recent developments in structural heart disease among interventional cardiologists have harbingered an entire distinct, less invasive approach to the management of MV disease. Kohorst and Pretorious impart a meticulous review of future technology for MV repair and replacement. 38 They have successfully summarized all the minimally invasive techniques under development by areas of targets, namely, the leaflets, annulus, chordae, and replacement. If anything, this approach in itself instills that MV is an extremely complex structure and should be viewed as "MV-apparatus" rather than just a "valve."
Last but not the least, an excellent review by Maxwell and Whitener on reviewing emerging data on repairing significant MR at the time of LVAD placement. 39 Treatment of mitral stenosis has been universally acceptable during LVAD surgery, but the jury is out for the management of MR in LVAD patients. With growing patient population for LVAD destination therapy in the near future we may have better data to guide therapy for MR in LVAD patients.
Overall, this edition of the Seminars in Cardiothoracic and Vascular Anesthesia is an excellent collection of contemporary reviews on the assessment and management of MV disease that is important for both the novice and experienced practitioners. Recent focus of centers experienced in treating MV disease is to provide a personalized treatment that fits best the needs of the individual patient. Inspiration of hybrid techniques and nontraditional "out-of-box" 7, [40] [41] [42] approaches to specific conditions are being fortified. What is remarkable about MV disease treatment is that not one modality is better than the rest, but the fact that no one treatment may meet the complexity of the management entirely. Since the inception of Carpentier's repair for MV, today we are privileged with an assortment of options for our patients, past needing to replace the valve.
Armed with a comprehensive knowledge provided by the reviews of our themed issue on the contemporary management of MV disease and its related conditions, one would be curious to find out what would be the most adequate management of that 40-year old patient whose case was presented in the opening paragraph; the patient underwent a mini-mitral approach (thoracotomy) failed neochordoplasty with partial resection, and a complete ring annuloplasty with mild to moderate residual MR. Shared decision and preemptive planning with the patient was implied that in case repair fails, partial correction may result in another 5 to 10 years of symptom-free survival after which she may be a candidate for TMVR (hence the full annuloplasty ring) or an open-heart valve replacement if she would choose, which would then technically qualify her as a patient without a history of redo-sternotomy.
